Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 173

1.

Ten common questions (and their answers) about off-label drug use.

Wittich CM, Burkle CM, Lanier WL.

Mayo Clin Proc. 2012 Oct;87(10):982-90. doi: 10.1016/j.mayocp.2012.04.017.

2.

Drug, patient, and physician characteristics associated with off-label prescribing in primary care.

Eguale T, Buckeridge DL, Winslade NE, Benedetti A, Hanley JA, Tamblyn R.

Arch Intern Med. 2012 May 28;172(10):781-8. doi: 10.1001/archinternmed.2012.340.

PMID:
22507695
3.

Off-label drug use: the bevacizumab story.

Stewart MW.

Mayo Clin Proc. 2013 Mar;88(3):305. doi: 10.1016/j.mayocp.2012.12.007. No abstract available.

PMID:
23489456
4.

In reply.

Wittich CM, Burkle CM, Lanier WL.

Mayo Clin Proc. 2013 Mar;88(3):305-6. doi: 10.1016/j.mayocp.2012.12.008. No abstract available.

PMID:
23489457
5.

Off-label prescribing among office-based physicians.

Radley DC, Finkelstein SN, Stafford RS.

Arch Intern Med. 2006 May 8;166(9):1021-6.

PMID:
16682577
6.

Off-label prescribing patterns of antidepressants in children and adolescents.

Lee E, Teschemaker AR, Johann-Liang R, Bazemore G, Yoon M, Shim KS, Daniel M, Pittman J, Wutoh AK.

Pharmacoepidemiol Drug Saf. 2012 Feb;21(2):137-44. doi: 10.1002/pds.2145.

PMID:
21538674
7.

U.S. physician knowledge of the FDA-approved indications and evidence base for commonly prescribed drugs: results of a national survey.

Chen DT, Wynia MK, Moloney RM, Alexander GC.

Pharmacoepidemiol Drug Saf. 2009 Nov;18(11):1094-100. doi: 10.1002/pds.1825.

PMID:
19697444
8.

Evaluation of unlicensed and off-label antiepileptic drugs prescribed to children: Brazilian Regulatory Agency versus FDA.

Borges AP, Campos MS, Pereira LR.

Int J Clin Pharm. 2013 Jun;35(3):425-31. doi: 10.1007/s11096-013-9755-2.

PMID:
23430533
9.

Off-label medication use in adult critical care patients.

Lat I, Micek S, Janzen J, Cohen H, Olsen K, Haas C.

J Crit Care. 2011 Feb;26(1):89-94. doi: 10.1016/j.jcrc.2010.06.012.

PMID:
20716478
10.

Off-label prescriptions: how to identify them, frame them, announce them and monitor them in practice?

Le Jeunne C, Billon N, Dandon A; participants of round table N° 3 of Giens XXVIII (th)., Berdaï D, Adgibi Y, Bergmann JF, Bordet R, Carpentier A, Cohn E, Courcier S, Girault D, Goni S, Jolliet P, Liard F, Prot-Labarthe S, Simon T, Vernotte C, Westerloppe J.

Therapie. 2013 Jul-Aug;68(4):225-39. doi: 10.2515/therapie/2013041. English, French.

11.

Positive outcomes through the appropriate use of off-label prescribing.

Bright JL.

Arch Intern Med. 2006 Dec 11-25;166(22):2554-5; author reply 2555. No abstract available.

PMID:
17159026
12.

Access to anticancer drugs: many evidence-based treatments are off-label and unfunded by the Pharmaceutical Benefits Scheme.

Mellor JD, Van Koeverden P, Yip SW, Thakerar A, Kirsa SW, Michael M.

Intern Med J. 2012 Nov;42(11):1224-9. doi: 10.1111/j.1445-5994.2012.02751.x.

PMID:
22372936
13.

Off-label prescribing in the treatment of dermatologic disease.

Sugarman JH, Fleischer AB Jr, Feldman SR.

J Am Acad Dermatol. 2002 Aug;47(2):217-23.

PMID:
12140467
14.

[Off-label prescriptions in public psychiatric hospital practice].

Andréoli L, Gaudoneix M, Beauverie P, de Beaurepaire R.

Therapie. 2013 Nov-Dec;68(6):347-59. doi: 10.2515/therapie/2013054. French.

PMID:
24246118
15.

Off-label antidepressant use in children and adolescents compared with young adults: extent and level of evidence.

Czaja AS, Valuck R.

Pharmacoepidemiol Drug Saf. 2012 Sep;21(9):997-1004. doi: 10.1002/pds.3312.

PMID:
22760843
16.

Direct-to-consumer prescription drug advertising: trends, impact, and implications.

Wilkes MS, Bell RA, Kravitz RL.

Health Aff (Millwood). 2000 Mar-Apr;19(2):110-28. Review.

17.

[Assessment off-label prescribing in Dermatology].

Picard D, Carvalho P, Bonnavia C, Louin L, Josset V, Lauret P, Joly P; Ensemble des Consultants de la Clinique Dermatologique du CHU de Rouen..

Ann Dermatol Venereol. 2003 May;130(5):507-10. French.

PMID:
12843825
18.

Off-label drug prescribing on a state university obstetric service.

Rayburn WF, Turnbull GL.

J Reprod Med. 1995 Mar;40(3):186-8.

PMID:
7776301
19.

Off-label drug use in human immunodeficiency virus disease.

Brosgart CL, Mitchell T, Charlebois E, Coleman R, Mehalko S, Young J, Abrams DI.

J Acquir Immune Defic Syndr Hum Retrovirol. 1996 May 1;12(1):56-62.

PMID:
8624761
20.

Off-label psychotropic prescribing for young persons in medium security.

Haw C, Stubbs J.

J Psychopharmacol. 2010 Oct;24(10):1491-8. doi: 10.1177/0269881109105102.

PMID:
19423609
Items per page

Supplemental Content

Support Center